Anti-Human IgE (Omalizumab) - 25 mg

All|Recombinant Antibodies>Biosimilar Recombinant Antibodies|Primary Monoclonal Antibodies

2 - 8°C Wet Ice

IgE is a pivotal antibody in allergic responses, crucially involved in conditions like allergicasthma. It binds to high-affinity receptors on mast cells and basophils, triggering the releaseof inflammatory mediators. The pathogenic role of IgE in allergic inflammation is well-documented, with multivalent allergens binding to allergen-specific IgEs on sensitizedeffector cells, leading to effector cell activation and the release of potent inflammatorymediators. Therapies targeting IgE, such as omalizumab, have shown efficacy in reducingexacerbations, symptoms, and medication use in allergic asthma, highlighting thesignificance of IgE in allergic diseases1, 2. RG-3648, commonly known as Omalizumab, is a humanized monoclonal antibody thattargets IgE, a key player in allergic responses. Approved for severe allergic asthma andchronic spontaneous urticaria, Omalizumab binds to serum IgE, preventing its interactionwith cellular IgE receptors. By downregulating high-affinity IgE receptors on inflammatorycells and reducing eosinophil numbers, Omalizumab improves respiratory symptoms, andquality of life, and reduces asthma exacerbations. Despite generally being well-tolerated, rareanaphylactic reactions have been reported. Omalizumab's efficacy extends to variousconditions like allergic rhinitis, atopic dermatitis, and nasal polyps, showcasing itstherapeutic versatility3, 4.

≥ 5.0 mg/ml

IgE is primarily found in the lungs, skin, and mucosal membranes.